Novartis' ($NVS) Gilenya, which a consumer watchdog group last year pegged with safety concerns, is again being called into question after a patient taking the ...

Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study Significant reduction in brain volume loss ...

The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple ...

Europe's drug regulator said it is reviewing the "benefits and risks" of Novartis' multiple-sclerosis drug Gilenya and recommended that doctors closely monitor the hearts of patients after they are ...

If you have a certain type of multiple sclerosis (MS), your doctor might suggest Gilenya (fingolimod) as a treatment option for you. Gilenya is a prescription medication that’s used to treat the ...

Novartis AG's Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in the ...

Oct. 18, 2013 -- The FDA is continuing to investigate a possible link between the multiple sclerosis drug Gilenya (fingolimod) and a case of a rare brain infection in a European patient. The patient ...

Novartis' ($NVS) multiple sclerosis drug Gilenya may be able to mitigate a painful side effect of chemotherapy in cancer patients, according to a new preclinical ...

Novartis asked high court to set aside mandate allowing generic versions of multiple-sclerosis drug Novartis argued it is likely to win Supreme Court challenge (Reuters) - The U.S. Supreme Court on ...

“For the first time, we have an FDA-approved treatment specifically for children and adolescents with multiple sclerosis,” explains Billy Dunn, M.D., director of the Division of Neurology Products in ...

Novartis’ multiple sclerosis therapy Gilenya was once proposed as a kidney disease treatment because its ability to modulate S1P receptors could theoretically tamp down inflammation. Although that ...